|
EP3587590A1
|
|
Nucleic acid depletion and detection
|
|
US2017102394A1
|
|
Method to optimize the treatment of patients with biological drugs
|
|
US2017234896A1
|
|
Lateral flow immunoassays for the detection of antibodies against biological drugs
|
|
GB201414350D0
|
|
Consensus-based allele detection
|
|
GB201304614D0
|
|
Genetic markers for osteoarthritis
|
|
EP2827706A1
|
|
Transgenic animal model of mood disorders
|
|
US2014255923A1
|
|
Discrimination of blood type variants
|
|
WO2012171990A1
|
|
Discrimination of blood type variants
|
|
WO2012038382A2
|
|
Markers for joint displasia, osteoarthritis and conditions secondary thereto
|
|
EP2565277A1
|
|
Method for predicting radiographic severity in ankylosing spondylitis
|
|
EP2471949A1
|
|
Method for the identification by molecular techniques of genetic variants that encode no D antigen (D-) and altered C antigen (C+W)
|
|
WO2011027219A1
|
|
High throughput detection of small genomic deletions and insertions
|
|
WO2011027218A1
|
|
High throughput detection of genomic copy number variations
|
|
EP2397561A1
|
|
Methods for determining the presence or absence of genetic segments
|
|
ES2395679A1
|
|
Method for the assessment of athlete behavior of a subject.
|
|
ES2361800A1
|
|
METHODS AND PRODUCTS FOR IN VITRO GENOTIPATE OF HUMAN GENETIC VARIATIONS ASSOCIATED WITH HUMAN Erythrocyte ANTIGENS.
|
|
ES2356458A1
|
|
METHODS AND PRODUCTS FOR IN VITRO GENOTIPATE OF HUMAN GENETIC VARIATIONS ASSOCIATED WITH REACTIONS ADVERSE TO DRUGS.
|
|
AU2008217662A1
|
|
Method and product for "in vitro" genotyping with application in anti-aging medicine
|
|
EP2049685A2
|
|
Method for prognosing osteoporosis phenotypes
|
|
WO2008010082A2
|
|
Diagnostic method for fibromyalgia (fms) or chronic fatigue syndrome (cfs)
|
